· The Health Policy Podcast
Health Policy Podcast logo

Receive new episodes in your inbox.

Dartmouth College logo

Organization

Dartmouth College

Dartmouth College 6101 Steele Hall Hanover, NH 03755

Dartmouth College is a private Ivy League research university founded in 1769 in Hanover, New Hampshire. It is one of the nine colonial colleges established before the American Revolution and is consistently ranked among the nation’s leading universities. Dartmouth enrolls approximately 4,400 undergraduate students and 2,000 graduate students across its undergraduate college and graduate and professional schools, including the Geisel School of Medicine, Thayer School of Engineering and Tuck School of Business. The college is known for its strong liberal arts curriculum, undergraduate focus and the flexible year-round Dartmouth Plan academic calendar.

Coverage areas

Guests (1)

Episodes (1)

  • 2026-08-20

    Chris Snyder Discusses FDA Drug Repurposing and Market Incentives

    with Christopher (Chris) Snyder

    In the latest episode of the Health Policy Podcast, Christopher Snyder, a professor at Dartmouth College, discusses the FDA's exploration of drug repurposing and the economic incentives surrounding it. Snyder explains how generic drugs often miss opportunities for secondary uses due to a lack of financial motivation for manufacturers after patent expiration. He also highlights the work of the Market Shaping Accelerator, a collaborative initiative aimed at enhancing innovation in public health and addressing market failures.

Notable quotes

  • The idea is that often a drug that was initially discovered for one use or another actually has a second life as a different use.
  • There's a study that suggests that there might be hundreds as many as eight hundred missing treatments of generics.
  • The thing is that that incentive doesn't hold for generic drugs.
  • Once a drug goes off patent, it turns out you can actually get a patent on second uses, but you can't monetize it.
  • The costs of the clinical trials are going to be lower for a generic because it's already been proven safe for the other use.
  • Our goal is like, how can we solve big social problems that seem intractable?